Axovant Gene Therapies Ltd (SIOX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
David W. Nassif
Employees:
40
11 TIMES SQUARE 33RD FLOOR, NEW YORK, NY 10036
877-746-4891

Sio Gene Therapies, Inc. focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease.

Data derived from most recent annual or quarterly report
Market Cap 25.44 Million Shares Outstanding73.739 Million Avg 30-day Volume 171.557 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.29
Price to Revenue0.0 Debt to Equity0.0 EBITDA-71.001 Million
Price to Book Value0.8128 Operating Margin0.0 Enterprise Value-15.861 Million
Current Ratio5.517 EPS Growth-0.581 Quick Ratio4.902
1 Yr BETA 1.1023 52-week High/Low 2.66 / 0.23 Profit Margin0.0
Operating Cash Flow Growth-29.5284 Altman Z-Score-16.3048 Free Cash Flow to Firm -41.194 Million
Earnings Report2022-08-11
View SEC Filings from SIOX instead.

View recent insider trading info

Funds Holding SIOX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SIOX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-14:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-27:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.02: Results of Operations and Financial Condition
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-18:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2022-02-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-02-09:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-25:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-11-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-12:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-01:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    NASSIF DAVID W. INTERIM CEO, CFO

    • Officer
    • Director
    546,500 2022-02-08 2

    MESWANI PARAG V CHIEF COMMERCIAL OFFICER

    • Officer
    153,700 2022-02-08 2

    CHERUVU PAVAN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    278,242 2021-12-08 1

    VUORI KRISTIINA MD

    • Director
    42,000 2021-04-15 0

    PANDE ATUL

    • Director
    42,000 2021-04-15 0

    MODIG BERNDT

    • Director
    42,000 2021-04-15 0

    TORTI FRANK

    • Director
    42,000 2021-04-15 0

    CORCORAN GAVIN CHIEF R&D OFFICER

    • Officer
    244,300 2021-04-15 0

    SUNDARAM SENTHIL VEL

    • Director
    42,000 2021-04-15 0

    ROIVANT SCIENCES LTD.

    • 10% Owner
    18,577,380 2020-02-24 0

    VENKER ERIC

    • Director
    0 2020-02-17 0

    VIKING GLOBAL PERFORMANCE LLC

    VIKING GLOBAL EQUITIES LP

    VIKING GLOBAL EQUITIES II LP

    VGE III PORTFOLIO LTD.

    VIKING GLOBAL EQUITIES MASTER LTD.

    VIKING LONG FUND GP LLC

    VIKING LONG FUND MASTER LTD.

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SHABET ROSE SHARON

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    No longer subject to file 2019-07-10 0

    VIKING GLOBAL INVESTORS LP

    VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

    VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

    VIKING GLOBAL OPPORTUNITIES GP LLC

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SHABET ROSE SHARON

    • 10% Owner
    • FORMER 10% OWNER FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    No longer subject to file 2019-07-10 0

    QVT ASSOCIATES GP LLC

    QVT FINANCIAL INVESTMENT CAYMAN LTD.

    • 10% Owner
    No longer subject to file 2019-07-10 0

    MACHADO PATRICK

    • FORMER 10% OWNER
    No longer subject to file 2019-07-10 0

    DEXXON HOLDINGS LTD.

    DEXCEL PHARMA TECHNOLOGIES LTD.

    OREN DAN

    • SEE REMARKSSEE REMARKSSEE REMARKS
    No longer subject to file 2019-07-10 0

    LO ANDREW

    • FORMER 10% OWNER
    No longer subject to file 2019-07-10 0

    SVF INVESTMENTS (UK) LTD

    SOFTBANK VISION FUND L.P.

    SVF GP (JERSEY) LTD

    SVF HOLDINGS (UK) LLP

    • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
    No longer subject to file 2019-07-10 0

    POTTER MYRTLE S

    • Director
    0 2019-04-15 0

    JEFFS ROGER

    • Director
    0 2019-04-15 0

    BICKERSTAFF GEORGE

    • Director
    0 2019-04-15 0

    BAZLEY MATHEW C. GENERAL COUNSEL

    • Officer
    0 2019-04-15 0

    VIKING GLOBAL EQUITIES MASTER LTD.

    • 10% Owner
    99,285,714 2019-01-01 0

    LOMBARDO ILISE CHIEF MEDICAL OFFICER

    • Officer
    0 2018-08-15 0

    OREN ILAN

    • Director
    0 2018-06-06 0

    WEINHOFF GREGORY M PRINCIPAL FINANCIAL OFFICER

    • Officer
    0 2018-03-15 0

    ALTMEYER MARK PRES (ASG) & CHIEF COMM. OFC.

    • Officer
    0 2018-03-15 0

    MOHR STEPHEN FREDERICK GENERAL COUNSEL

    • Officer
    0 2018-03-15 0

    HUNG DAVID PRINCIPAL EXECUTIVE OFFICER

    • Officer
    • Director
    0 2017-12-29 0

    DEXCEL PHARMA TECHNOLOGIES LTD.

    • 10% Owner
    75,000,000 2017-09-06 0

    SHABET ROSE SHARON

    • 10% Owner
    75,000,000 2017-07-01 0

    FALBERG KATHRYN E

    • Director
    0 2017-05-15 0

    VERNON W ANTHONY

    • Director
    0 2017-05-15 0

    FRIEDHOFF LAWRENCE MD PHD CHIEF DEVELOPMENT OFFICER

    • Officer
    0 2017-04-28 0

    OLANOFF LAWRENCE S

    • Director
    0 2017-04-28 0

    ADASCZIK MICHAEL PRINCIPAL ACCOUNTING OFFICER

    • Officer
    0 2017-04-28 0

    PISANO GARY P.

    • Director
    0 2017-04-28 0

    MCCOURT MARION PRINCIPAL OPERATING OFFICER

    • Officer
    0 2017-04-07 0

    VIKING GLOBAL PERFORMANCE LLC

    VIKING GLOBAL EQUITIES LP

    VIKING GLOBAL EQUITIES II LP

    VGE III PORTFOLIO LTD.

    VIKING LONG FUND MASTER LTD.

    VIKING LONG FUND GP LLC

    • 10% Owner
    75,000,000 2016-07-08 0

    VIKING GLOBAL INVESTORS LP

    VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP

    VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC

    VIKING GLOBAL OPPORTUNITIES GP LLC

    HALVORSEN OLE ANDREAS

    OTT DAVID C.

    SUNDHEIM DANIEL S.

    • 10% Owner
    75,000,000 2016-07-08 0

    QVT ASSOCIATES GP LLC

    QVT FUND V LP

    • 10% Owner
    75,000,000 2016-07-08 0

    DEXXON HOLDINGS LTD.

    OREN DAN

    • 10% Owner
    75,000,000 2016-07-08 0

    CVIJIC CHRISTINE MIKAIL CHIEF ADMIN OFFICER AND GC

    • Officer
    0 2016-04-29 0

    RAMASWAMY VIVEK PRINCIPAL EXECUTIVE OFFICER

    • Officer
    • Director
    • 10% Owner
    0 2016-04-29 0

    ROMEO MARIANNE L. HEAD,GLOBAL TRANS & RISK MGMT

    • Officer
    • Director
    0 2016-04-29 0

    ROEMER ALAN S. PRINCIPAL FIN & ACCT OFFICER

    • Officer
    0 2015-06-10 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    SIO GENE THERAPIES INC SIOX 2022-08-11 22:15:03 UTC 0.9115 1.4085 2400000
    SIO GENE THERAPIES INC SIOX 2022-08-11 21:45:04 UTC 0.9115 1.4085 2400000
    SIO GENE THERAPIES INC SIOX 2022-08-11 21:15:03 UTC 0.9115 1.4085 2400000
    SIO GENE THERAPIES INC SIOX 2022-08-11 20:45:04 UTC 0.9115 1.4085 2400000
    SIO GENE THERAPIES INC SIOX 2022-08-11 20:15:03 UTC 0.9115 1.4085 2400000
    SIO GENE THERAPIES INC SIOX 2022-08-11 19:45:04 UTC 0.9115 1.4085 2400000
    SIO GENE THERAPIES INC SIOX 2022-08-11 19:15:05 UTC 0.9115 1.4085 2400000
    SIO GENE THERAPIES INC SIOX 2022-08-11 18:45:03 UTC 0.9115 1.4085 2400000
    SIO GENE THERAPIES INC SIOX 2022-08-11 18:15:05 UTC 0.9115 1.4085 2400000
    SIO GENE THERAPIES INC SIOX 2022-08-11 17:45:05 UTC 0.9115 1.4085 2400000
    SIO GENE THERAPIES INC SIOX 2022-08-11 17:15:05 UTC 0.9115 1.4085 2400000
    SIO GENE THERAPIES INC SIOX 2022-08-11 16:45:04 UTC 0.9115 1.4085 2400000
    SIO GENE THERAPIES INC SIOX 2022-08-11 16:15:05 UTC 0.9115 1.4085 2400000
    SIO GENE THERAPIES INC SIOX 2022-08-11 15:45:05 UTC 0.9115 1.4085 1700000
    SIO GENE THERAPIES INC SIOX 2022-08-11 15:15:03 UTC 0.9115 1.4085 1700000
    SIO GENE THERAPIES INC SIOX 2022-08-11 14:45:06 UTC 0.9115 1.4085 1700000
    SIO GENE THERAPIES INC SIOX 2022-08-11 14:15:04 UTC 0.9115 1.4085 1700000
    SIO GENE THERAPIES INC SIOX 2022-08-11 13:45:04 UTC 0.8152 1.5048 1700000
    SIO GENE THERAPIES INC SIOX 2022-08-11 13:15:04 UTC 0.8152 1.5048 1700000
    SIO GENE THERAPIES INC SIOX 2022-08-11 12:45:04 UTC 0.8152 1.5048 1700000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments